The private equity market is splitting at the seams. Megadeal activity through the first nine months of 2025 ran 31% above 2024’s count, with 47 transactions of $5 billion or more, per PwC. That concentration at the top leaves the middle market to a different competitive set — one that JP Conte has been operating in for years through Lupine Crest Capital. His read on where patient capital wins in the current deal environment is shaping the firm’s positioning for 2026.
Lupine Crest’s deal envelope sits below the level where sovereign wealth funds and continuation vehicles dominate. That keeps the firm out of the most overpriced segment of the market by design. What remains in the middle market is still competitive — mid-sized sponsors losing megadeal targets are moving down the size curve, intensifying competition in the next tier. Family offices operating with permanent capital and no committee approval move faster on operating asset due diligence than their fund-stage peers. That speed is structural, not circumstantial, and the current pricing environment is making it more valuable than it has been in years.
The sectors where JP Conte’s team focuses — healthcare, financial services, software, and industrial technology — are areas where operating expertise and long hold periods produce the most value. Fund-stage sponsors underwriting against a five-year exit timetable price risk differently than a family office that can hold through a full business cycle. PwC notes that the median age of exited companies in H1 2025 sat around six years, and PE firms are still carrying assets from 2017 and 2018 vintage funds — a direct product of pricing in an exit timeline that didn’t hold.
That inventory pressure doesn’t affect Jean-Pierre Conte’s firm the same way because there are no LP redemption windows forcing a sale. His multi-decade track record across capital cycles means sellers who value execution certainty over headline price know Lupine Crest delivers. The J-P Conte Family Foundation, established in 2017, channels the same long-horizon philosophy into his philanthropic commitments across education, medical research, and conservation — a consistent pattern in how he deploys capital.